In short
Clinical trials are studying N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N'-(2-METHOXYETHYL)SULFURIC DIAMIDE in adults with chronic kidney disease and type 1 diabetes. The trial aims to compare kidney-related outcomes, especially urine albumin levels, in people with elevated urinary albumin excretion. It is a Phase 2 study, but this specific trial was withdrawn.
Key points
- One clinical trial studied N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N'-(2-METHOXYETHYL)SULFURIC DIAMIDE in adults with chronic kidney disease and type 1 diabetes. The trial was Phase 2 and planned to enroll 36 people with elevated urinary albumin excretion. It compared the study drug alone with a combination of dapagliflozin and the study drug. The main outcome was change in urine albumin-creatinine ratio, a test that shows how much albumin is in the urine. This specific trial was withdrawn.
Trial overview
The clinical trial NCT06072326 was an interventional study, which means researchers planned to assign treatments and then measure what happened.1 It studied N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N'-(2-METHOXYETHYL)SULFURIC DIAMIDE in adults with chronic kidney disease and type 1 diabetes.1
The brief summary says the study aimed to compare dapagliflozin plus the study drug versus the study drug alone for albuminuria, which means too much albumin in the urine.1
Who was studied
The target population was adults with type 1 diabetes and chronic kidney disease who had elevated urinary albumin excretion.1 This means the study focused on people whose kidneys were already affected and who were losing extra albumin in the urine.1
The trial planned to enroll 36 participants.1 That small number is common in early-stage studies that look closely at whether a treatment may help in a specific group.1
What the study measured
The main endpoint was the change from baseline in urine albumin-creatinine ratio (UACR).1 Baseline means the starting measurement before treatment begins.1 UACR is a urine test that helps show how much albumin is leaking into the urine, so it is often used to track kidney-related changes.1
The primary comparison was SC0062 alone versus the combination of dapagliflozin and SC0062.1 The source data do not list other outcomes, so the main focus described here is the UACR result.1
Trial phase and status
This study was in Phase 2.1 Phase 2 trials usually look more closely at whether a treatment may work in a defined patient group while continuing safety checks.1
The trial status was Withdrawn.1 In practical terms, this means the study did not go ahead as planned and the source data do not provide trial results.1
Key patient terms
Albuminuria means too much albumin is present in the urine, which can be a sign of kidney damage.1 Combination treatment means two treatments are used together in the same study.1
Elevated urinary albumin excretion means the body is passing more albumin into the urine than normal.1 In this trial, that feature helped define who could be studied.1